This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study ECOG E1A11.
View study details on ClinicalTrials.gov
Subjects, 18 y/o and older, who are diagnosed with symptomatic standard-risk multiple myeloma (SR-MM).
June 01, 2018